From Los Angeles Business Journal · Hannah Welk · · 40s
ImmunityBio Drug Approved for Common Bladder Cancer
FDA approves ImmunityBio's Anktiva for more common bladder cancer type.
In brief
FDA approves ImmunityBio's Anktiva for more common bladder cancer type. FDA grants ImmunityBio's Anktiva expanded use for papillary tumors in bladder cancer after months of review. Originally reported by Los Angeles Business Journal.
FDA Approval for Anktiva
ImmunityBio's Anktiva now approved by FDA for more common bladder cancer type with papillary tumors.
Earlier Than Expected
FDA approval came months ahead of deadline after initial 2024 approval for rare bladder cancer form.
Stock Reaction
Stock rose 4% on Oct 14 but fell back to Sept 28 low since then.
Expanded Use Process
FDA rejected expanded use in early 2025, requiring more data before Jan 6, 2027 decision.
The key point
FDA grants ImmunityBio's Anktiva expanded use for papillary tumors in bladder cancer after months of review.
/https://i.s3.glbimg.com/v1/AUTH_37554604729d4b2f9f3eb9ad8a691345/internal_photos/bs/2026/0/A/BKzGCvS1mwY8PA23HvwQ/foto04bra-201-roadmap-a2.jpg)
/https://i.s3.glbimg.com/v1/AUTH_37554604729d4b2f9f3eb9ad8a691345/internal_photos/bs/2026/x/j/aED8bBRrSIT2fK7mObbQ/foto05agr-101-ouro-b11.jpg)